Alder Biopharmaceuticals Inc buy stratec
Start price
06.11.18
/
50%
€12.72
Target price
04.11.21
€25.26
Performance (%)
32.88%
End price
05.11.21
-
Summary
This prediction is currently being closed. The BUY prediction by stratec for Alder Biopharmaceuticals Inc has seen massive gains of 32.88%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alder Biopharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | -0.676% | 4.053% | 2.212% | 52.786% |
| iShares Nasdaq 100 | 0.993% | 10.872% | 38.041% | 94.873% |
| iShares Nikkei 225® | 3.279% | 13.468% | 59.003% | 70.295% |
| iShares S&P 500 | 0.621% | 6.195% | 26.154% | 68.910% |
Comments by stratec for this prediction
In the thread Alder Biopharmaceuticals Inc diskutieren
Alder auf dem Weg, eine Best-in-Class-Therapie gegen Migräne zu entwickeln.
Eptinezumab wird derzeit in mehreren globalen, randomisierten, zulassungsrelevanten Phase-3-Studien untersucht, um seine Wirksamkeit und Sicherheit in der Migräneprävention zu bewerten. Bislang wurden mehr als 3.100 Patienten in das klinische Entwicklungsprogramm aufgenommen.
H. Lundbeck A/S (OTC:HLUKF) has agreed to acquire Alder BioPharmaceuticals (NASDAQ:ALDR) for $18 per share in cash plus one non-tradeable Contingent Value Right (CVR) for an additional $2 per share if migraine med eptinezumab is approved by the European Medicines Agency (EMA). The total value of the transaction is up to $1.95B.
In the thread Trading Alder Biopharmaceuticals Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten